Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.

NCT02716077 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT02716077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02716077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Not applicable
Overall status
Terminated
Start date
March 31, 2016
Completion date
March 31, 2021
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii nodal or intransit disease or resectable stage iv melanoma